Japan will reduce the NHI price of Amgen’s thyroid eye disease therapy Tepezza (teprotumumab) by 5.5% under the cost-effectiveness assessment (CEA) scheme, effective November 1. The Central Social Insurance Medical Council (Chuikyo) approved the revised NHI prices at its general…
To read the full story
Related Article
- Paxlovid, Awiqli Braced for NHI Price Cuts after CEAs
June 25, 2026
- Tepezza, Trodelvy Headed for NHI Price Cuts after CEAs
May 14, 2026
REGULATORY
- CEA Review Has not Settled Debate, LDP Lawmaker Says
September 15, 2026
- Japan Pharma Investment Subgroup to Hold 1st Meeting September 18
September 14, 2026
- Japan Formally Joins Project Orbis for Cancer Drug Reviews
September 14, 2026
- MHLW Seeks 20.6 Billion Yen for MCM Stockpiles, Revenue Guarantees
September 14, 2026
- Japan Panel Backs Mandatory Medical Data Sharing by Major Hospitals
September 14, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





